Announcements Trials
Browse Landscape

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 36NIH 12INDUSTRY 4OTHER_GOV 3

Study Type

Interventional 19Observational 4

Sponsor

Cancer Type

CNS 4

Conditions

Breast Neoplasms 468Neoplasms 316Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 208Lung Neoplasms 178Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 60Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Neurofibromatosis 1 × Clear all
NCT06360406 2026-06-01

Real-World Treatment Study of Koselugo (Selumetinib)

AstraZeneca

Recruiting
200 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT07221331 2026-04-16

PRECIOUS Egypt

AstraZeneca

Recruiting
200 enrolled
CNS

Neurofibromatosis 1

NCT05388370 2026-03-12

PASS of Paediatric Patients Initiating Selumetinib

AstraZeneca

Active not recruiting
124 enrolled
CNS

Neurofibromatosis 1

NCT05683678 2025-04-04

US Selumetinib Registry

Alexion Pharmaceuticals, Inc.

Terminated
37 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡